Biomarker Analysis in Patients with Rheumatoid Arthritis & Systemic Lupus Erythematosus Treated with CLN-978, a Bispecific CD19 x CD3 T Cell Engager
- Assessment of the peripheral blood and tissue B cell depletion following CLN-978 treatment
- Characterization of the effect of CLN-978 treatment on disease activity in early dose escalation cohorts in both RA and SLE
- Evaluation of the impact of CLN-978 on serological markers of disease activity (autoantibody levels) and vaccine titers